News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioVentrix to Exhibit Revivent™ System, which Surpasses Survival Benefit Threshold for Heart Failure Treatment, at European Heart Failure Congress


5/22/2013 11:08:03 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LISBON, Portugal--(BUSINESS WIRE)--BioVentrix, pioneer of the Less Invasive Ventricular Enhancement™ (LIVE™) procedure for the treatment of heart failure (HF), announced today that it will showcase its Revivent™ Myocardial Anchoring System at the European Heart Failure Congress (HFC) 2013, May 25-27 in Lisbon, Portugal. In clinical studies, the Revivent technology has demonstrated the ability to exceed a recently defined threshold for improving survival in HF patients. Data from a recent subgroup analysis of the National Institute of Health (NIH)-sponsored Surgical Treatment for Ischemic Heart Failure (STICH) study concluded that reducing the volume of the left ventricle (LV) to less than 60mL/m2 provided a statistically significant improvement in survival for patients suffering from HF1.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES